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Schistosomiasis (bilharzia) is a neglected tropical disease which
affects more than 200 million humans, primarily in the developing
world [1]. It results from infection by parasitic worms from the
genus Schistosoma. Current control relies largely on the anthelmin-
thic drug praziquantel (PZQ). In some countries with high rates of
infection, mass drug administration schemes are being applied to
populations to reduce overall levels of infection and transmission
[2]. There have been several reports of reduced efﬁcacy of this drug
and resistance can be induced in experimentally infected animals
treated with PZQ, although both of these effects are species depen-
dant [3,4]. While resistance is not currently considered a major
threat, the emergence of resistance to the drugs of choice in other
parasitic infections (e.g., of Fasciola spp. towards triclabendazole)
suggest that, in time, selective pressures will result in the
emergence of clinically signiﬁcant resistance. Furthermore, whilst
treatment with PZQ is effective in controlling morbidity and
transmission, total elimination from an individual is rare due to
lower susceptibility to PZQ in developing schistosomes (somules)
[3]. Consequently, considerable efforts are being made to identify
vaccines and new drugs to combat the disease.In recent years, there has been renewed interest in targeting
metabolic enzymes in the treatment of infectious diseases [5].
Although the high levels of sequence and structural similarity
between the host and pathogen enzymes make the design of spe-
ciﬁc inhibitors challenging, the essential nature of key metabolic
enzymes means that their inhibition will be highly detrimental
to the pathogen. A key enzyme in glycolysis is triose phosphate
isomerase EC 5.3.1.1; TPI). The splitting of fructose 1,6-bisphos-
phate results in two three carbon monophosphorylated carbohy-
drates, glyceraldehyde 3-phosphate and dihydroxyacetone
phosphate. While glyceraldehyde 3-phosphate can proceed in the
glycolytic pathway, dihydroxyacetone phosphate cannot. TPI
catalyses the conversion of dihydroxyacetone phosphate into
glyceraldehyde 3-phosphate, thus enabling these three carbon
atoms to be processed in the glycolytic pathway. Without this
reaction, there would be no net production of ATP by glycolysis
and, thus, for many organisms no means of synthesising ATP under
anaerobic conditions. In humans hereditary deﬁciency of TPI can
result in disease [6,7]. The pathology of disease arises largely from
misfolding of the enzyme or its failure to dimerise and consequent
loss of enzymatic activity [8–10]. The main, detrimental effect on
the cell is the build-up of dihydroxyacetone phosphate, which
appears to be toxic when present in higher than normal concentra-
tions [11,12]. Inhibition of TPI with b-carbolines causes similar
outcomes to TPI deﬁciency [13]. Thus, it seems likely that selective
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organism and thus represents a potential therapeutic strategy.
There is also considerable interest in TPI from Schistosoma spe-
cies as a vaccine target [14–17]. Interestingly, this glycolytic en-
zyme is not only found in the cytoplasm of cells; it is also
secreted [18–20]. Its role as a secreted protein is unclear, although
in some pathogenic microbes it has a role in the recognition of cell
surface and extracellular matrix glycoproteins [21–24]. Experi-
mental trials are encouraging, with vaccination of several different
experimental animals against Schistosoma TPI reducing the level
and duration of infection [25–30]. This approach has also been
adopted in other parasites. Monoclonal antibodies raised against
TPI have been shown to reduce the growth of the protozoan Try-
panosoma cruzi, the tick Rhipicephalus (Boophilus) microplus and
the tapeworm Taenia solium [31–33]. This strengthens the argu-
ment that TPI is a potential vaccine target in a variety of pathogens.
Toadvancework indrugandvaccinediscovery, fundamental bio-
chemical information on the enzyme is desirable. Here, we report
the biochemical characterisation of TPI from Schistosoma mansoni.
2. Materials and methods
2.1. Expression and puriﬁcation of SmTPI
Total RNA was extracted from the cercariae of a Puerto Rican
strain of S. mansoni as previously described [34]. cDNA was
produced using Superscript II RT (Life Technologies) and random
hexamers (Promega, UK) from 1 lg total RNA according to the
manufacturer’s instructions. SmTPI (GeneDB accession
Smp_003990) was ampliﬁed using PCR to generate full length
CDS with restriction sites (Primer 1 TATCTAGAGAT-
GTCTGGATCTCGC (XbaI); Primer 2 ATCTCGAGTCAACGTTGTCTGG
(XhoI)). PCR produced a product of 780 bp (Supplementary
Fig. S1) which matched the size of the predicted gene model
Smp_003990. The SmTPI amplicon was cloned into the pGEX GST
fusion protein bacterial expression system. Expression of proteins
alongside a GST fusion partner has been demonstrated to increase
solubility of co-expressed fusion partners and the high afﬁnity of
GST for glutathione Sepharose allows stringent washing with high
salt and detergent to remove contaminating bacterial proteins [35].
For these reasons it is routinely used over other commonly used
expression systems for the production of enzymes and proteins
for serological studies [36,37]. Subsequent restriction digestion of
the vector-insert construct with XbaI and XhoI revealed successful
insertion of the 780 bp PCR product (Fig. S1). Sequencing of the
construct showed that the sequence of SmTPI was identical to that
of the gene model Smp_003990 except for a synonymous mutation
(C? T) at position 495 (Fig. S2A), which did not result in modiﬁca-
tion of the translated protein sequence (Fig. S2B).
pGEX-KG-SmTPI constructs were transformed into TG2 Escheri-
chia coli cells for GST-fusion protein expression. Expression and
puriﬁcation were performed as previously described [37]. Brieﬂy,
cultures of transformed E. coli (4 l) were produced and fusion pro-
tein production induced at an OD600 of 0.4–0.8 for 3 h with 1 mM
IPTG at 37 C. Cells were lysed by three passages through a French
press cell at 10000 psi and fusion protein isolated from lysates
using an AKTAprime with a Glutathione Sepharose 4B (GS4B;
5 ml) column (GE Healthcare). Eluted proteins were reattached to
GS4B and washed with PBS plus 1% (v/v) Triton X-100 (pH 7.4)
and PBS plus 1 M NaCl (pH 7.4). SmTPI was separated from the
GST fusion partner by on column digestion with 30 U/mg fusion
protein thrombin (GE healthcare) in either PBS or PBS plus 0.1%
(v/v) Tween 20. Free GST and thrombin were removed from the ﬁ-
nal preparation by incubation at 4 C for 30 min with 10% (v/v)
GS4B and 1 ll/U thrombin p-aminobenzamidine agarose (Sigma),
respectively.2.2. Molecular modelling
The sequence of SmTPI (XP_002571861) was submitted to the
Phyre2 protein modelling server (www.sbg.bio.ic.ac.uk/phyre2/)
using the intensive mode [38]. Two copies of the resulting, mono-
meric model were aligned with the two subunits in human TPI
(PDB: 2JK2 [39]) and combined into a single pdb ﬁle. This structure
was solvated and energy minimised using YASARA (www.yasara.
org/minimizationserver.htm) [40].
2.3. Analytical methods
Crosslinking was carried out using bis(sulphosuccinimidyl)
suberate (BS3) [41] and limited proteolysis with chymotrypsin
and subtilisin as previously described [42]. Protein melting tem-
peratures were determined by thermal scanning ﬂuorimetry
(TSF) [43] as previously described [42].
Analytical gel ﬁltration was carried out using a Sephacryl 300
(Sigma) column of total volume (Vt) 49.5 ml, equilibrated in buffer
G (50 mM Tris–HCl, 17 mM Tris-base, 150 mM sodium chloride, pH
7.4 [44]). Proteins were applied (volumes 6250 ll) and resolved in
buffer G at a ﬂow rate of 1 ml min1. Fractions (1 ml) were
collected and protein detected by measuring A280nm and 10%
SDS–PAGE. Elution volumes (Ve) for SmTPI and standards (b-galac-
tosidase (116 kDa), bovine serum albumin (66.2 kDa), chymotryp-
sinogen A (25 kDa), and Ribonuclease A (13.7 kDa) were measured.
The void volume (V0) was estimated to be 17 ml by measuring Ve
for blue dextran. These values were used to calculate the partition
coefﬁcient, Kav according to Kav = (Ve  V0)/(Vt  V0).
2.4. Enzyme kinetics
Measurement of the rate of isomerisation of both dihydroxyac-
etone phosphate and glyceraldehyde 3-phosphate was based on
published methods [45,46] as described previously for Fasciola
hepatica TPI [42].
3. Results
3.1. SmTPI is a dimer and is predicted to have a similar overall fold
to mammalian TPI
SmTPI can be expressed in, and puriﬁed from, E. coli as a GST-fu-
sion. The GST moiety can be successfully cleaved, leaving puriﬁed
SmTPI (Fig. 1a). The protein is a dimer as judged by protein–protein
crosslinking and analytical gel ﬁltration (Fig. 1b and c). The
presence of ligands did not affect the pattern of crosslinking, sug-
gesting that they do not induce conformational changes which
can be detected by this method (Fig. 1b).
A homology model of dimeric SmTPI was constructed (Supple-
mentary data). The protein is predicted to have the typical b-barrel
fold seen in TPI from other species (Fig. 2a). The amino acid se-
quence has 64% identity and 75% similarity to the human enzyme;
the predicted overall fold is highly similar to the human enzyme
(PDB: 2JK2 [39]) with a route mean squared deviation (rmsd) of
0.701 Å over 3156 equivalent atoms. It is also highly similar to
two insect TPI enzymes – Tenebrio molitor (PDB 2I9E;
rmsd = 0.929 Å over 3112 equivalent atoms) and R. microplus
(3TH6; rmsd = 0.983 Å over 3146 equivalent atoms) [47,48]. Bioin-
formatics analysis has identiﬁed a tripeptide motif (SXD/E, where X
is any amino acid) present in parasitic helminths, which is not
present in free living ones and it has been suggested that this motif
may form part of a unique epitope not present in the host enzyme
[17]. In SmTPI, the sequence comprises Ser-157, Ala-158 and
Asp-159 and is predicted to extend an a-helix on the surface of
the protein (Fig. 2).
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Fig. 1. Expression, puriﬁcation and dimerisation of SmTPI. (a) The puriﬁcation of SmTPI was followed by 10% SDS–PAGE. The masses of molecular mass markers (M) are
shown to the left of the gel in kDa. The GST-SmTPI fusion was the major band in the following expression and cell lysis (L); the majority of the protein bound to the
glutathione resin and was not present in the ﬂow through (F); SmTPI could be eluted by thrombin (E⁄ in the presence of tween; E in the absence of tween); this left GST bound
to the bead (B⁄ in the presence of tween and B in the absence). (b) SmTPI (25 lM) in the absence of crosslinker () ran as a single band of approximately 26 kDa. Following
reaction with BS3 (800 lM, +) a second band corresponding to approximately twice the monomeric molecular mass was observed. The amount and migration of this band
were unchanged in the presence of the ligands (10 mM): arsenate ions (A); phosphate ions (P); dihydroxyacetone phosphate (D); glyceraldehyde 3-phosphate (G). The masses
of molecular mass markers (M) are shown in kDa. (c) Elution of proteins in analytical gel ﬁltration of SmTPI was monitored by absorbance and resulted in a single peak
(Ve = 24 ml; left graph). SDS–PAGE (centre) demonstrated that this peak contained SmTPI. M, Molecular mass markers with masses in kDa (25 and 35 kDa markers are
shown); C, SmTPI (30 lM; indicated by an arrow); 23–25, elution volumes of the corresponding fractions. A standard curve was used to estimate the molecular mass of SmTPI
(see Section 2; right). The arrow indicates the Kav of SmTPI (0.215).
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cysteine in the dimer interface. Compounds have been identiﬁed
which react with this cysteine and inactive the enzyme, but do
not react with mammalian TPI [49–53]. In SmTPI the structurally
equivalent residue to this reactive cysteine (Cys-14 in Entamoeba
histolytica TPI; 1M6J [50]; overall protein sequence similarity
66%) is Met-15. In Giardia lamblia TPI modiﬁcation of another
cysteine residue (Cys-222) by reagents which react with sulfhydr-
yls results in inactivation of the enzyme [54–56]. This residue is
conserved in SmTPI (Cys-221; overall similarity 68%) and is, thus,
a potential site for the design of inhibitors.
3.2. SmTPI shows high stability to proteolysis and thermal
denaturation
SmTPI was not noticeably affected by chymotrypsin under the
experimental conditions tested (Fig. 3a). Subtilisin (at concentra-
tions greater than 360 nM) was able to digest SmTPI; however
few discrete fragments were detected (Fig. 3b). Ligands had little
effect on the extent of digestion (Fig. 3c). SmTPI has a remarkably
high melting temperature (82.0 ± 0.7 C; Fig. 3d). Values for human
metabolic enzymes determined under similar conditions are
typically in the range 45–60 C [57,58]. The measured melting
temperature was unaffected by the addition of either substrate
(data not shown).
3.3. SmTPI has high turnover numbers and Michaelis constants
SmTPI exhibited Michaelis–Menten kinetics is both directions
(Fig. 4). The Michaelis constants for dihydroxyacetone phosphate
and glyceraldehyde 3-phosphate were 0.51 ± 0.06 and1.1 ± 0.2 mM, respectively. Turnover numbers were high; for dihy-
droxyacetone phosphate a value of 7800 ± 180 s1 was determined
and for glyceraldehyde 3-phosphate it was 6.9 ± 0.3 s1.
4. Discussion
Like previously characterised TPI enzymes, SmTPI is dimeric,
stable and has rapid reaction kinetics. The predicted structure is
highly similar to the enzymes from potential mammalian hosts;
thus, discovery of compounds which target SmTPI speciﬁcally will
be challenging. Subtle differences in the surface structure, for
example, the Ser-Ala-Asp tripeptide, presumably account for the
ability of some immunoglobulins to differentiate between the
parasite and human enzymes. The location of this peptide near
the surface of the protein (Fig. 2b) is consistent with this
hypothesis.
SmTPI is remarkably stable to both proteolysis and thermal
denaturation, even in comparison with TPI from some other spe-
cies. Plasmodium falciparum TPI (amino acid similarity 60%) can
be completely digested by subtilisin in 15 min at a TPI:protease ra-
tio of 100:1 [59], whereas SmTPI remains partly undigested at sim-
ilar ratios after 30 min (Fig. 3b). In contrast TPI from T. cruzi and T.
brucei (66% and 68% similarity, respectively) were resistant to deg-
radation (TPI:subtilisin of 100:1) over a period of hours with the T.
brucei being particularly resistant [60]. However, despite this resis-
tance to proteolysis, the melting temperature for T. brucei TPI is
53.1 C (by CD spectroscopy) nearly 30 K below that measured
for SmTPI [49]. The melting temperature of human TPI was esti-
mated as 66.2 C by differential scanning calorimetry (DSC) [61].
The precise molecular causes and biological signiﬁcance of SmTPI’s
thermal stability remain to be discovered. It has been shown that
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Fig. 2. Predicted structure of SmTPI. (a) The overall fold of SmTPI is predicted to be
a dimer of two b-barrel containing monomers (yellow and blue); the SXD motif is
shown in purple in both monomers. (b) A close up of the SXD motif in SmTPI
compared to the structurally equivalent region from the human enzyme (2JK2 [39]).
SmTPI is shown in yellow and purple, with purple representing residues (Ser-Ala-
Asp) for which the side chains are also shown. Human TPI is shown in light green.
Fig. 4. Steady-state enzyme kinetics of SmTPI. The initial rate of reaction catalysed
by SmTPI with was measured as a function of dihydroxyacetone phosphate and
glyceraldehyde 3-phosphate concentration. Each point represents the mean of three
separate determinations and the error bars the standard deviations of these means.
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(66% similarity) increased the melting temperature by 26 K [62].
The structurally equivalent residue in SmTPI is Gln-65. However,(a)
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Fig. 3. Thermal and proteolytic stability of SmTPI. (a) Exposure of SmTPI (30 lM) to chy
little digestion detectable by 15% Tris–tricine SDS–PAGE. (b) SmTPI (30 lM) resisted d
digestion could be detected by 15% SDS–PAGE. (c) Digestion of SmTPI (30 lM) was not
phosphate (D), glyceraldehyde 3-phosphate (G), phosphate ions (P), arsenate ions (A). In (
derivative of the melting curve of SmTPI (1.8 lM) in the absence of ligands. The peak inthis is not sufﬁcient to explain completely SmTPI’s high melting
temperature. F. hepatica TPI (80% similarity) also has a glutamine
at this position, but this enzyme has a melting temperature
(measured under the same conditions as SmTPI) of 67.0 C [42].(b)
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[Sublisin]/nM
(d)
6 
6 
5 
5 
8 
5 
4 
motrypsin (concentrations indication above the gel) for 30 min at 37 C resulted in
igestion by subtilisin up to 90 nM (at 37 C for 30 min); at higher concentrations
affected by the absence () or presence of the ligands (10 mM): dihydroxyacetone
a), (b) and (c), the masses of molecular mass markers (M) are shown in kDa. (d) First
this curve represents the maximum gradient in the melting curve and, thus, the Tm.
3426 V.L. Zinsser et al. / FEBS Letters 587 (2013) 3422–3427The steady-state kinetic parameters for SmTPI are similar to
those recorded for the enzyme from other species. Schistosoma
japonicum TPI (92% similarity) has a Km for glyceralderhyde 3-
phosphate of 410 lM, just under half the value for SmTPI [63].
For F. hepatica TPI this value is 660 lM and its Km for dihydroxyac-
etone phosphate is 2300 lM, approximately four times that for
SmTPI. The human enzyme has Km values for both substrates in
the hundreds of micromolar range [64]. This suggests that it would
be difﬁcult to discover compounds which discriminate between
the active sites of the human and parasite TPI enzymes. Neverthe-
less, it may be possible to exploit relatively minor differences. This
approach has been successful in other species. P. falciparum TPI
dimerization can be disrupted by peptides which mimic the dimer
interface [65]. Dithiodianiline and phenazine inactivate T. cruzi TPI
through modiﬁcations of the dimer interface [66,67]. Thus, it may
be possible to discover reagents which selectively disrupt the
homodimerisation of SmTPI or otherwise disrupt its enzymatic
function.
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